Clinical Trials · NCT06073184

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium

Phase
Phase 2
Recruitment status
Recruiting
Sponsor
GynOncTrials
Enrollment
71
Start date
Sep 2026
Locations
1 site, Canada
Primary endpoint
Assessment of Complete Pathologic Response
View Semaglutide compound reference